We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04349280
Recruitment Status : Active, not recruiting
First Posted : April 16, 2020
Last Update Posted : September 23, 2022
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or locally advanced urothelial cancer. This trial provides the first evaluation of bintrafusp alfa in participants with urothelial cancer that has progressed following platinum therapy.

Condition or disease Intervention/treatment Phase
Neoplasms Drug: Bintrafusp alfa Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is a single arm study.
Masking: None (Open Label)
Masking Description: This is an open label study.
Primary Purpose: Treatment
Official Title: A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent
Actual Study Start Date : October 15, 2020
Estimated Primary Completion Date : November 2, 2022
Estimated Study Completion Date : August 31, 2023

Arm Intervention/treatment
Experimental: Participants receiving bintrafusp alfa
Participants will receive bintrafusp alfa.
Drug: Bintrafusp alfa
Participants will receive bintrafusp alfa.

Primary Outcome Measures :
  1. Confirmed overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 assessed by Investigator [ Time Frame: Up to 3 years ]

Secondary Outcome Measures :
  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Up to 3 years ]
  2. Number of participants with AEs by their severity [ Time Frame: Up to 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants can give signed informed consent/assent.
  • Participants with histologically confirmed locally advanced or metastatic or locally advanced/unresectable urothelial carcinoma (including renal, pelvis, ureter, urinary bladder, urethra).
  • Able to provide, a tumor tissue sample collected during screening and prior to administration of bintrafusp alfa.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
  • Participants with adequate organ system functions.
  • Life expectancy of at least 12 weeks.
  • A female is eligible if she is not pregnant or breastfeeding.

Exclusion Criteria:

  • Active brain and/or leptomeningeal disease that is symptomatic or requires therapeutic intervention. Participants with asymptomatic central nervous system (CNS) metastases who are clinically stable as demonstrated by serial brain images and have no requirement for corticosteroids for at least 14 days prior to enrollment are eligible.
  • History of malignancy other than urothelial cancer within the last 3 years except for localized tumors that have been treated with curative intent or have not required therapy in the past 2 years. (e.g., resected non-melanoma skin cancer).
  • No more than 2 lines of systemic therapy for the treatment of metastastic disease. If the most recent therapy was not a platinum-based regimen, the participant must have progressed on or after that therapy.
  • Cirrhosis or current unstable liver or biliary disease per investigator assessment.
  • Current pneumonitis or history of non-infectious pneumonitis that required systemic immunosuppressive treatment.
  • Active autoimmune disease that required systemic immunosuppressive treatment within the past 2 years.
  • Received prior allogeneic/autologous bone marrow or solid organ transplant.
  • Receiving systemic corticosteroids (>10 milligrams [mg] daily oral prednisone or equivalent) or other immunosuppressive agent within 7 days prior to study treatment. Inhaled or topical steroids are permitted.
  • Known severe hypersensitivity reactions to monoclonal antibodies or any ingredient used in the study treatment formulation (Grade >=3 National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0).
  • Active infection requiring systemic therapy.
  • Received any live vaccine within 30 days prior first dose of intervention.
  • Known history of positive test for human immunodeficiency virus (HIV) with the exception of participants with cluster of differentiation 4 (CD4) + T-cell (CD4+) counts >=350 cells per microliter (cells /uL) and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections.
  • Active hepatitis B virus (HBV) (HBV surface antigen-positive).
  • Active hepatitis C virus (HCV) infection, or positive HCV antibody, with the exception of participants that 1. Have HCV viral load below the limits of quantitation and 2. Completed curative antiviral therapy or are receiving and compliant with antiviral therapy.
  • History or evidence of cardiac abnormalities within the 6 months prior to first dose of intervention.
  • Participants with history of bleeding diathesis or recent major bleeding events considered by the Investigator as high risk for investigational drug treatment are also excluded.
  • Any other serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the participant to receive protocol therapy, or interfere with the interpretation of study results.
  • Received prior systemic anti-cancer therapy within 2 weeks prior to study treatment.
  • Received prior therapy with an anti-programmed death 1 (PD-1), anti-programmed death Ligand 1 (anti-PD-L1), anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
  • Received prior therapy targeting transforming growth factor (TGF) beta - (e.g., Galunistertib).
  • Received radiation therapy (or other non-systemic disease therapy) within 2 weeks prior to study treatment.
  • Undergone major surgery within 4 weeks prior to administration of study treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04349280

Layout table for location information
United States, New York
GSK Investigational Site
Lake Success, New York, United States, 11041
United States, Ohio
GSK Investigational Site
Cincinnati, Ohio, United States, 45229
GSK Investigational Site
Columbus, Ohio, United States, 43210
United States, Virginia
GSK Investigational Site
Fairfax, Virginia, United States, 22031
United States, Washington
GSK Investigational Site
Seattle, Washington, United States, 98109
Canada, Ontario
GSK Investigational Site
Toronto, Ontario, Canada, M5G 2M9
GSK Investigational Site
Bordeaux, France, 33000
GSK Investigational Site
Poitiers Cedex, France, 86021
GSK Investigational Site
Toulouse Cedex 9, France, 31059
GSK Investigational Site
Villejuif Cedex, France, 94805
GSK Investigational Site
Amsterdam, Netherlands, 1066 CX
GSK Investigational Site
Barcelona, Spain, 08035
GSK Investigational Site
Madrid, Spain, 28040
GSK Investigational Site
Madrid, Spain, 28041
GSK Investigational Site
Sevilla, Spain, 41013
United Kingdom
GSK Investigational Site
London, United Kingdom, EC1A 7BE
Sponsors and Collaborators
Merck KGaA, Darmstadt, Germany
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT04349280    
Other Study ID Numbers: 213152
First Posted: April 16, 2020    Key Record Dates
Last Update Posted: September 23, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
URL: http://clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by GlaxoSmithKline:
Bintrafusp Alfa
Platinum Agent
Response Evaluation Criteria in Solid Tumors
Urothelial Cancer